BioDelivery Sciences to present at the Stifel Nicolaus 2012 Healthcare Conference (PRNewswire) - Aug 29, 2012 - Anticipated clinical and commercial update on BEMA buprenorphine/naloxone (BNX) and BEMA buprenorphine
Anticipated conference • Pain
|
|
Dr. Sirgo will focus on BDSI's progress with the clinical development program and the market opportunity for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence. Additionally, Dr. Sirgo will discuss BDSI's worldwide licensing and development agreement with Endo Heath Solutions (Endo) for BEMA Buprenorphine for the treatment of chronic pain and the recently initiated Phase 3 clinical program...
[IR5]
|